Precigen Overview

  • Founded
  • 1998
Founded
  • Status
  • Public
  • Employees
  • 283
Employees
  • Stock Symbol
  • PGEN
Stock Symbol
  • Investments
  • 25
  • Share Price
  • $7.28
  • (As of Monday Closing)

Precigen General Information

Description

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Contact Information

Formerly Known As
Intrexon Corporation, Genomatix, Intrexon
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 20358 Seneca Meadows Parkway
  • Germantown, MD 20876
  • United States
+1 (301) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Precigen Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.28 $7.74 $2.14 - $11.10 $1.5B 206M 1.39M -$1.02

Precigen Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 1,998,514 1,998,514 1,045,910 997,692
Revenue 103,178 103,178 90,722 151,178
EBITDA (72,864) (72,864) (141,327) (385,844)
Net Income (170,521) (170,521) (322,324) (509,336)
Total Assets 314,587 314,587 455,763 716,177
Total Debt 182,283 182,283 232,666 212,161
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Precigen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Precigen‘s full profile, request access.

Request a free trial

Precigen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regu
Biotechnology
Germantown, MD
283 As of 2020
00000
000000000 00000

0000000

erit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidat
0000 000000000
La Jolla, CA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000000

d do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostr
0000000000000
Saint-Herblain, France
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Precigen Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inhibrx Formerly VC-backed La Jolla, CA 00 00000 00000000 00000
0000000 Formerly VC-backed Saint-Herblain, France 000 00000 00000000 00000
00000000 Venture Capital-Backed Berkeley, CA 00 0000 00000000000 0000
000000000 0000 Venture Capital-Backed Madison, WI 00 00.000 0000000000 00.000
0000000 0000000000 Formerly VC-backed Redwood City, CA 000 00000 000000000 00000
You’re viewing 5 of 38 competitors. Get the full list »

Precigen Executive Team (35)

Name Title Board Seat Contact Info
Helen Sabzevari Chief Executive Officer & Board Member
John McLean President, Intrexon Crop Protection
Rick Sterling Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Donald Lehr JD Chief Legal Officer, Legal
Thomas Reed Ph.D Chief Scientific Officer & Founder
You’re viewing 5 of 35 executive team members. Get the full list »

Precigen Board Members (11)

Name Representing Role Since
Cesar Alvarez JD Self Board Member 000 0000
Dean Mitchell Self Board Member 000 0000
Fred Hassan Self Board Member 000 0000
Helen Sabzevari Precigen Chief Executive Officer & Board Member 000 0000
James Turley Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Precigen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Precigen Investments & Acquisitions (25)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 09-Nov-2017 0000 0000000000 00.00 Pharmaceuticals
000000 16-Jun-2017 000000000000000000 000.00 Pharmaceuticals 000000 0000 00.0
000000 00000000000 27-Sep-2016 000000000 Biotechnology
00000000 000 00000 04-Apr-2016 00000 0000000 Drug Discovery 000000 000000 00
Enviroflight 25-Feb-2016 Merger/Acquisition Other Agriculture 00000 0000
You’re viewing 5 of 25 investments and acquisitions. Get the full list »

Precigen Subsidiaries (6)

Company Name Industry Location Founded
Exemplar Genetics Biotechnology Sioux Center, IA 2008
0000000 0000000000 Biotechnology Budapest, Hungary 0000
00000000 Biotechnology San Diego, CA 0000
000000 Other Agriculture Abingdon, United Kingdom 0000
000000 Pharmaceuticals Gaithersburg, MD 0000
You’re viewing 5 of 6 subsidiaries. Get the full list »

Precigen Exits (5)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000000 25-Feb-2016 000000000000000000 Completed
  • 2 buyers
00000000 000000000 20-Apr-2015 000000000000000000 000.00 Completed
  • 00000000
00000000 000000000 27-Mar-2015 0000 0000 Completed
  • 7 buyers
0000000000 0000000 31-Oct-2012 000000000 00000000 000 Completed
  • 00000000
Ziopharm Oncology 12-Jan-2011 PIPE 000.00 Completed
To view Precigen’s complete exits history, request access »